查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726299

全球基因疗法起始材料市场：市场规模、份额、趋势分析（按产品、开发阶段、应用、最终用途和地区）、细分市场预测（2025-2030 年）

Gene Therapy Starting Materials Market Size, Share & Trends Analysis Report By Product (Viral Vectors, Plasmid DNA, Cell Lines), By Development Stage, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

基因治疗起始材料市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球基因治疗起始材料市场预计到2030年将达到54亿美元，2025年至2030年期间的复合年增长率为19.24%。

这一增长是由对高品质原料不断增长的需求推动的，这些原材料旨在支持针对罕见疾病、遗传疾病、癌症和其他复杂疾病的基因疗法的不断增长。随着越来越多的治疗方法通过临床试验并获得监管部门的核准，对可扩展、符合 GMP 的质体、病毒载体和其他关键投入的需求持续成长。

此外，技术进步、研发投入的增加以及法律规范也进一步推动了市场的发展。此外，生物技术公司和製造商之间的合作旨在提高生产能力并确保供应链的一致性，这将使基因治疗起始材料产业在整个预测期内实现强劲而持续的成长。

COVID-19 疫情凸显了快速治疗开发和可扩展製造的必要性，进一步加速了对基因治疗起始材料的需求。这刺激了对先进生物生产基础设施的投资，增加了对基因平台的关注，并刺激了质体DNA、病毒载体以及用于疫苗和基因疗法开发的其他关键组件的增长。

此外，不断扩大的基因治疗管道也推动了市场的成长。随着越来越多的治疗方法通过临床试验并获得监管部门的核准，对质体DNA 和病毒载体等高品质起始材料的需求持续增加。这导致对製造能力、先进技术和战略伙伴关係的投资增加，以实现高效的扩大规模和供应，满足世界各地基因治疗开发商不断变化的需求。

然而，围绕安全、品质和合规性的严格监管要求可能会减缓基因治疗产品的开发和核准。虽然这些规定对于确保患者安全至关重要，但它们通常涉及复杂的文件、大量的测试和漫长的审查时间。这会减缓市场进入速度、增加营运成本，并为缺乏监管专业知识的小型公司设置障碍。随着产业的发展，满足这些要求对于基因治疗起始材料市场的相关人员来说仍然是一个重大挑战。

基因治疗起始材料市场报告重点

  • 病毒载体领域凭藉其高基因传递效率和在核准的基因疗法中的广泛应用，在 2024 年占据市场最大收入份额，达到 42.91%。然而，预计在预测期内质体DNA 片段的复合年增长率最快，为 20.13%。
  • 根据开发阶段，由于越来越多的基因疗法候选药物进入临床试验，预计临床实验药物将在 2024 年占据最大的市场占有率。另一方面，临床前阶段药物预计在预测期内将呈现最快的复合年增长率。
  • 根据应用，肿瘤学领域预计将在 2024 年占据最大的收益占有率，并在预测期内以最快的复合年增长率成长。这是由于癌症发生率不断上升、临床研发管线不断健全以及针对各种肿瘤类型的基因疗法日益普及。然而，预计遗传疾病领域在预测期内将以复合年增长率大幅增长。
  • 根据最终用途，生物製药和製药公司部门在 2024 年收益占有率，这得益于对基因治疗研发、内部製造能力和战略伙伴关係关係的投资不断增加，以加速治疗发展。另一方面，预计 CRO/CMO 部门在预测期内将实现最快的复合年增长率。
  • 由于强大的研发投入、先进的製造能力以及产业领袖的集中，北美在 2024 年的收入份额方面占据市场主导地位。预计在预测期内亚太地区将以最快的复合年增长率成长。

目录

第一章 分析方法与范围

第二章执行摘要

3. 基因治疗起始材料市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 基因治疗起始材料市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章基因治疗起始材料市场：按产品分類的估计和趋势分析

  • 特定于产品的仪表板
  • 全球基因疗法起始材料市场：按产品进行的差异分析
  • 全球基因疗法起始材料市场：按产品分類的市场规模预测和趋势分析（2018-2030）
  • 病毒载体
    • 病毒载体市场规模、预测与趋势分析（2018-2030）
    • 腺病毒
    • 逆转录病毒
    • 腺结合病毒（AAV）
    • 慢病毒
    • 其他的
  • 质体DNA
    • 2018-2030年质体DNA市场规模、预测及趋势分析
  • 细胞株
    • 2018-2030年细胞株市场规模、预测与趋势分析
  • 其他的
    • 2018-2030年其他市场规模、预测与趋势分析

第五章基因治疗起始材料市场：依发展阶段的估计与趋势分析

  • 每个开发阶段的仪表板
  • 全球基因治疗起始材料市场：依发展阶段变化分析
  • 全球基因疗法起始材料市场：按发展阶段分類的市场规模预测和趋势分析（2018-2030）
  • 临床前阶段药物
    • 临床前治疗：市场规模预测与趋势分析（2018-2030）
  • 临床实验药物
    • 临床实验试验药物：市场规模预测与趋势分析（2018-2030）
  • 非处方药
    • 非处方药：市场规模预测与趋势分析（2018-2030）

第六章基因治疗起始材料市场：按应用的估计和趋势分析

  • 用于特定目的的仪表板
  • 全球基因治疗起始材料市场：依应用进行变异分析
  • 全球基因治疗起始材料市场：市场规模预测与应用趋势分析（2018-2030）
  • 瘤
    • 肿瘤学：市场规模预测与趋势分析（2018-2030）
  • 感染疾病
    • 感染疾病：市场规模预测与趋势分析（2018-2030）
  • 遗传性疾病
  • 其他的
    • 其他：市场规模预测及趋势分析（2018-2030年）

第七章基因治疗起始材料市场：按最终用途分類的估计和趋势

  • 按最终用途分類的仪表板
  • 全球基因治疗起始材料市场：以最终用途的变化分析
  • 全球基因疗法起始材料市场：按最终用途分類的市场规模预测和趋势分析（2018-2030）
  • 生物製药和製药公司
    • 生物製药和製药公司：市场规模预测和趋势分析（2018-2030）
  • 合约研究团队・合约行销团队
    • CRO/CMO：市场规模预测与趋势分析（2018-2030）
  • 其他的
    • 其他：市场规模预测及趋势分析（2018-2030年）

第八章基因治疗起始材料市场：区域估计和趋势分析

  • 各地区市场占有率分析（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与企业
  • 企业市场分析（2024年）
  • 战略地图
  • 参与企业概况
    • 查尔斯河实验室
    • 赛默飞世尔科技公司
    • 金斯瑞
    • 龙沙
    • 康泰伦特
    • 欧陆科技
    • 丹纳赫
    • 默克公司
    • Revvity公司
    • 赛多利斯公司
Product Code: GVR-4-68040-553-8

Gene Therapy Starting Materials Market Growth & Trends:

The global gene therapy starting materials market size is anticipated to reach USD 5.40 billion by 2030 and is projected to grow at a CAGR of 19.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

Gene Therapy Starting Materials Market Report Highlights:

  • The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.
  • Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.
  • Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.
  • Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.
  • North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Development Stage
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Gene Therapy Starting Materials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Genetic and Rare Diseases
      • 3.2.1.2. Expanding Pipeline of Gene Therapies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Strict Regulatory Requirements
  • 3.3. Gene Therapy Starting Materials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Therapy Starting Materials Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Global Gene Therapy Starting Materials Market Product Movement Analysis
  • 4.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Viral Vectors
    • 4.4.1. Viral Vectors Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 4.4.2. Adenovirus
      • 4.4.2.1. Adenovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Retrovirus
      • 4.4.3.1. Retrovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Adeno-Associated Virus (AAV)
      • 4.4.4.1. Adeno-Associated Virus (AAV) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Lentivirus
      • 4.4.5.1. Lentivirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. Plasmid DNA
    • 4.5.1. Plasmid DNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.6. Cell Lines
    • 4.6.1. Cell Lines Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Gene Therapy Starting Materials Market: Development Stage Estimates & Trend Analysis

  • 5.1. Development Stage Segment Dashboard
  • 5.2. Global Gene Therapy Starting Materials Market Development Stage Movement Analysis
  • 5.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Pre-clinical Therapeutics
    • 5.4.1. Pre-clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.5. Clinical Therapeutics
    • 5.5.1. Clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.6. Marketed Therapeutics
    • 5.6.1. Marketed Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Gene Therapy Starting Materials Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Global Gene Therapy Starting Materials Market Application Movement Analysis
  • 6.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
  • 6.5. Infectious Disease
    • 6.5.1. Infectious Disease Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
  • 6.6. Genetic Disease
    • 6.6.1. Genetic Disease Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)

Chapter 7. Gene Therapy Starting Materials Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Global Gene Therapy Starting Materials Market End Use Movement Analysis
  • 7.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Biopharmaceutical & Pharmaceutical Companies
    • 7.4.1. Biopharmaceutical & Pharmaceutical Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 7.5. CROs & CMOs
    • 7.5.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 7.6. Other
    • 7.6.1. Other Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 8. Gene Therapy Starting Materials Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Strategy Mapping
  • 9.4. Participants Overview
    • 9.4.1. Charles River Laboratories
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. GenScript
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Lonza
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Catalent
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Eurofins Scientific
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Danaher
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Merck KGaA
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Revvity, Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Sartorius AG
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 3 North America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 5 North America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 North America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 7 US Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 8 US Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 9 US Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 10 US Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 11 Canada Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Canada Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 13 Canada Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 17 Mexico Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 19 Europe Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 Europe Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 22 Europe Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 24 UK Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 25 UK Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 26 UK Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 27 UK Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 28 Germany Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Germany Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 30 Germany Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 31 Germany Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 32 Italy Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Italy Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 34 Italy Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Italy Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 36 France Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 37 France Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 38 France Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 France Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 40 Spain Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 41 Spain Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 42 Spain Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 Spain Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 Sweden Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 46 Sweden Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Sweden Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 48 Denmark Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 49 Denmark Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 50 Denmark Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 51 Denmark Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 52 Norway Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 53 Norway Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 54 Norway Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 55 Norway Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 61 China Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 62 China Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 63 China Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 64 China Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 65 Japan Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Japan Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 67 Japan Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 68 Japan Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 69 India Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 70 India Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 71 India Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 72 India Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 74 South Korea Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 75 South Korea Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 76 South Korea Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 77 Australia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 78 Australia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 79 Australia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 80 Australia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 82 Thailand Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 83 Thailand Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 84 Thailand Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 86 Latin America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 87 Latin America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 88 Latin America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 89 Latin America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 91 Brazil Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 92 Brazil Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 93 Brazil Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 96 Argentina Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 97 Argentina Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 98 Middle East Africa Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 99 Middle East Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 100 Middle East Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 101 Middle East Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 102 Middle East Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 105 South Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 106 South Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 111 UAE Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 112 UAE Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 113 UAE Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 114 UAE Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market formulation & Validation
  • Fig. 6 Gene Therapy Starting Materials Market: Market Outlook
  • Fig. 7 Parent Market Outlook
  • Fig. 8 Related/Ancillary Market Outlook
  • Fig. 9 Gene Therapy Starting Materials Market Driver Impact
  • Fig. 10 Gene Therapy Starting Materials Market Restraint Impact
  • Fig. 11 Gene Therapy Starting Materials Market Strategic Initiatives Analysis
  • Fig. 12 Gene Therapy Starting Materials Market: Product Movement Analysis
  • Fig. 13 Gene Therapy Starting Materials Market: Product Outlook and Key Takeaways
  • Fig. 14 Viral Vectors Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Adenovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Retrovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Adeno-Associated Virus (AAV) Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Lentivirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cell Lines Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Plasmid DNA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Gene Therapy Starting Materials Market: Development Stage Movement Analysis
  • Fig. 24 Gene Therapy Starting Materials Market: Development Stage Outlook and Key Takeaways
  • Fig. 25 Pre-clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Marketed Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Gene Therapy Starting Materials Market: Application Movement Analysis
  • Fig. 29 Gene Therapy Starting Materials Market: Application Outlook and Key Takeaways
  • Fig. 30 Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infectious Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Genetic Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Other Disease Diagnostic Applications Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Gene Therapy Starting Materials Market: End-Use Movement Analysis
  • Fig. 37 Gene Therapy Starting Materials Market: End-Use Outlook and Key Takeaways
  • Fig. 38 Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Global Gene Therapy Starting Materials Market: Regional Movement Analysis
  • Fig. 42 Global Gene Therapy Starting Materials Market: Regional Outlook and Key Takeaways
  • Fig. 43 North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 US Country Dynamics
  • Fig. 45 US Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada Country Dynamics
  • Fig. 47 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico Country Dynamics
  • Fig. 49 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK Country Dynamics
  • Fig. 52 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany Country Dynamics
  • Fig. 54 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France Country Dynamics
  • Fig. 56 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy Country Dynamics
  • Fig. 58 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain Country Dynamics
  • Fig. 60 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark Country Dynamics
  • Fig. 62 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden Country Dynamics
  • Fig. 64 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway Country Dynamics
  • Fig. 66 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China Country Dynamics
  • Fig. 69 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan Country Dynamics
  • Fig. 71 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India Country Dynamics
  • Fig. 73 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand Country Dynamics
  • Fig. 75 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea Country Dynamics
  • Fig. 77 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia Country Dynamics
  • Fig. 79 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil Country Dynamics
  • Fig. 82 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina Country Dynamics
  • Fig. 84 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa Country Dynamics
  • Fig. 87 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia Country Dynamics
  • Fig. 89 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE Country Dynamics
  • Fig. 91 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait Country Dynamics
  • Fig. 93 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market Position of Key Market Players